Trial Profile
Six week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Mar 2021
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer; Viatris Inc
- 05 Dec 2011 Planned number of patients (221) added as reported by ClinicalTrials.gov record (Extension trial: NCT00265382).
- 05 Dec 2011 Planned number of patients (221) added as reported by ClinicalTrials.gov record (Extension trial: NCT00265382).
- 05 Dec 2011 Planned end date (Jun 2009) added as reported by ClinicalTrials.gov record (Extension trial: NCT00265382).